Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | Software (Web Marketplace Saas..) • IT (& TMT) • Media • Education • BioTech • FinTech (& Financials services) • HealthTech (& Fitness) • Insurance (& InsurTech) • Medical Devices (& Hospital Services) • Healthcare (& Wellness) • Pharmaceutical (& Medicine) • Woman Focused |
Stages | Seed, Startup, Early Stage, Expansion, Later Stage, Series A, Series B, Pre-seed |
Investing | United States • United Kingdom • Sweden • Israel • Europe |
Investment Range | $100,000 - $5,000,000 |
Investment Sweet Spot | $1,500,000 |
Assets Under Management | $2,000,000,000 |
SV Health Investors is a venture capital firm with a strong focus on the healthcare sector, leveraging their expertise in equity investments to empower innovators aimed at improving patient lives. Founded in 1993 and headquartered at 71 Kingsway, London, WC2B 6ST, United Kingdom, SV Health Investors fosters growth from seed to later-stage companies through its investment activities. The firm has a diverse portfolio that covers a broad spectrum of the healthcare industry, including Software (Web Marketplace SaaS, etc.), IT & TMT, Media, Education, BioTech, FinTech & Financial Services, HealthTech & Fitness, Insurance & InsurTech, Medical Devices & Hospital Services, Healthcare & Wellness, Pharmaceutical & Medicine, and Woman Focused sectors. SV Health Investors is known for its contributions to medical device, life sciences, healthcare services, digital health and biotechnology sectors, primarily in the United States and Europe. The firm's investment parameters range from a minimum of $100,000 to a maximum of $1,500,000, with the sweet spot being at the maximum value, highlighting their capability to support ventures through significant funding. With specialities that include Seed, Startup, Early Stage, Expansion, Later Stage, Series A, Series B, and Pre-seed investments, SV Health Investors utilizes its $2 billion assets under management to foster growth and innovation. Celebrating a 30-year track record in the US and UK, their commitment includes backing inspiring and talented innovators with diverse experiences to create healthcare industry leaders. The firm looks for compelling teams and technologies that have the potential to change medicine and deliver therapeutic breakthroughs. Their global private equity and venture capital investment platform is specialized and diversified across healthcare funds, focused on strategies such as biotechnology, which includes dementia investments, healthcare growth equity, and medtech. With more than 50 investment professionals based in Boston and London, they bring talent and experienced industry veterans to add value and guide strategic direction. They are a signatory to the commitment that diversity, including under-represented groups, adds to the success of businesses.